From Insight to Impact
A Paradigm Shift in Brugada Syndrome Management: The BRAVE Study
What is Brugada syndrome?
Brugada syndrome (BrS) is a heart condition that changes the way the heart's electrical system controls the heartbeat. Most people feel fine most of the time, but dangerous heart rhythms can cause fainting or, in rare cases, sudden death. Because it can run in families, doctors may recommend heart tests for relatives as well.
Research shows that rare genetic variants in the SCN5A gene, which controls the heart's sodium channel, as well as common noncoding variants in the same region, are strongly linked to this condition, increasing the risk of dangerous arrhythmias. With appropriate treatment and regular monitoring, the risks linked to this condition can be significantly reduced. Dr. Koonlawee Nademanee and colleagues recently published the groundbreaking BRAVE trial, the first randomized study testing catheter ablation for Brugada syndrome patients with ICDs. With nearly a 70% reduction in ventricular arrhythmias compared to standard care, with over 80% of patients remaining VF-free after a single procedure, these findings mark a major step beyond ICD dependency, demonstrating ablation as a proactive, life-saving therapy.
Powered by FlippingBook